Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(93)
•••
Comment by MasterAlgaeon Sep 24, 2020 12:05am
232 Views
Post# 31609590

RE:RE:I am of the opinion

RE:RE:I am of the opinion
Well SternIR is going to produce some results this week or next by getting some US coverage, according to the CEO of Antibe. That new American coverage may provide some share interest - retail spillover perhaps. The 'interest' will depend on the caliber/reputation of the company engaged in the coverage.
 
The company has not announced any upcoming studies on 352 and 340 and the most recent scientific/medical journal articles are March and April on those, so that info is already in the stock price. The market already knows that the entire pipeline has profound positive effects. What the market does not know are long-term or even short-term side effects, so that too is in the market. So here we sit - the market is down just over 9% compared to this time last year, and down over 20% so far this year.

The CEO said he has no idea why the stock is down. Maybe the Bloom Burton consortium that sold a 1/4 of the company in the last dilution has some ideas as to why the loss? Shoulder shrug? Anyone?
 
The sale of the dental-tool and putty company will not likely bring in any significant money, I'd optimistically expect its sale to be neutral to positive. It would be great if they could make money on the sale.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities